ClinicalTrials.gg
CompletedNCT01822899Updated Sep 6, 2017Results posted

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Umeclidinium bromide/Vilanterol and Placebo ACCUHALER/DISKUS in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 79 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
717
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 3 under way, 1 of them phase 3. vilanterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
14th of 48
717 · median 168
Started
2013
with 1 other
Phase 3
19 of 48
none open now
Registered
30th of 48
by date
Lead sponsor
41 of 48
GlaxoSmithKline

Among the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, this one is the 14th largest by enrollment, is one of 2 that started in 2013, is one of 19 in phase 3, and was the 30th registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing vilanterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC) in subjects with Chronic Obstructive Pulmonary Disease (COPD). Subjects who meet the eligibility criteria at Screening will complete a 7 to 14 day Run-in period. At the end of the run-in period, approximately 710 eligible subjects will be equally randomized (to complete at least 568 evaluable subjects) to one of the 2 treatment groups for 12 weeks: 1. UMEC/VI 62.5/25 micrograms (mcg) administered as one inhalation once-daily in the morning via the Novel dry powder inhaler (NDPI) + placebo administered as one inhalation each morning and evening via single multidose powdered inhaler (ACCUHALER/DISKUS) or 2. FSC 500/50 mcg administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once-daily in the morning via NDPI. A safety Follow-up assessment will be conducted approximately 7 days after the end of the study treatment (Early Withdrawal, if applicable). The total duration of subject participation will be approximately 15 weeks.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Novel Dry Powder Inhaler (NDPI)
  • umeclidinium bromide (UMEC)
  • GSK573719
  • lung function
  • GW642444
  • salmeterol (SAL)
  • fluticasone propionate (FP)
  • vilanterol (VI)
  • Chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient
  • : A signed and dated written informed consent prior to study participation
  • Age: Subjects 40 years of age or older at Visit 1
  • Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile); or Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the acceptable methods listed in the protocol used consistently and correctly
  • Diagnosis: established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society as follows: Chronic obstructive pulmonary disease is a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
  • Smoking history: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years [number of pack years = (number of cigarettes per day/20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar smoking cannot be used to calculate pack year history.
  • Severity of disease: A pre and post-salbutamol /FVC ratio of \<0.70 and a post-salbutamol FEV1 of >=30% and \<=70% of predicted normal values calculated using NHANES III reference equations at Visit 1.
  • Dyspnea: A score of >=2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
  • Asthma: A current diagnosis of asthma
  • Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject, who, in the opinion of the investigator, has any other significant respiratory condition in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Inactive tuberculosis in more than one lobe is exclusionary. Allergic rhinitis is not exclusionary.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • : A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, , lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.
  • Hospitalization: Hospitalization for pneumonia within 12 weeks prior to Visit 1
  • History of COPD Exacerbation: A documented history of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics, and/or hospitalization. Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1)
  • 12-Lead : An abnormal and significant electrocardiogram (ECG) finding from the 12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility.
  • Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1: Depot corticosteroids - 12 weeks, Systemic, oral or parenteral corticosteroids - 6 weeks, Antibiotics (for lower respiratory tract infection) - 6 weeks, Cytochrome P450 3A4 strong inhibitors - 6 weeks, Herbal medications potentially containing oral or systemic steroids - 6 weeks, Inhaled corticosteroids (ICS) - 30 days, Long-acting beta2-agonist (LABA)/ICS combination products - 30 days, Phosphodiesterase 4 (PDE4) inhibitors (e.g., roflumilast) - 14 days, Inhaled long-acting anticholinergics - 7 days, Theophyllines - 48 hours, Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton) - 48 hours, Oral beta2-agonists Long-acting-48 hours/Short-acting - 12 hours, Inhaled long acting beta2-agonists (LABA, e.g., salmeterol, formoterol, indacaterol) - 48 hours, Inhaled sodium cromoglycate or nedocromil sodium - 24 hours, Inhaled short acting beta2-agonists - 4 hours, Inhaled short-acting anticholinergics - 4 hours, Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products - 4 hours, Any other medication - 30 days or within 5 drug half-lives (whichever is longer)
  • Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., \<=12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator
  • Inability to read: A subject will not be eligible for the study if in the opinion of the investigator the subject cannot read.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
717 participants (actual)

Study arms

  • Experimental
    Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS

    Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.

    Drug: Umeclidinium bromide/Vilanterol · Drug: Placebo ACCUHALER/DISKUS

  • Active comparator
    Fluticasone propionate/Salmeterol + placebo NDPI

    Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.

    Drug: Fluticasone propionate/Salmeterol · Drug: Placebo NDPI

Interventions

  • DrugUmeclidinium bromide/Vilanterol

    Drug pages: Umeclidinium bromide · Vilanterol

    Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).

  • DrugPlacebo ACCUHALER/DISKUS

    Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).

  • DrugFluticasone propionate/Salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).

  • DrugPlacebo NDPI

    Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5 and 15 minutes and 1, 3, 6, 9, 12 (pre-evening dose), 13, 15, 18, 23, and 24 hours after the morning dose. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline FEV1 (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), and smoking status.

    Time frame: Baseline and Day 84

Secondary outcomes

  1. Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. BL is defined as the mean of the assessments made 30 and 5 minutes (min) pre-dose on Treatment Day 1. Trough FEV1 on Day 85 is defined as the mean of the FEV1values obtained 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 85 is the mean of the FEV1 values obtained 23 and 24 hours after morning dosing on Day 84). Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, day, and day by BL and day by treatment interactions. The model used all available trough FEV1 values recorded on Days 28, 56, 84, and 85. Missing data were not directly imputed in this analysis; however, all non-missing data for a participant were used within the analysis to estimate the treatment effect for trough FEV1 at Day 85.

    Time frame: Baseline and Day 85

07

Results

Posted May 29, 2014

Participant flow

Participants who met the eligibility criteria at Screening (Visit 1) completed a 7- to 14-day Run-in Period, followed by a 12-week Treatment Period.

Participant flow — Overall Study
MilestoneUMEC/VI 62.5/25 µgFSC 500/50 µg
Started358358
Completed334340
Not completed2418
Withdrew: Adverse event65
Withdrew: Lack of efficacy63
Withdrew: Protocol violation63
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject57

Outcome measures

PrimaryChange From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5 and 15 minutes and 1, 3, 6, 9, 12 (pre-evening dose), 13, 15, 18, 23, and 24 hours after the morning dose. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline FEV1 (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), and smoking status.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84
LitersUMEC/VI 62.5/25 µgFSC 500/50 µg
Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 840.166 ± 0.01220.087 ± 0.0121
Statistical analysis
  • UMEC/VI 62.5/25 µg vs FSC 500/50 µg · ANCOVA · p = <0.001 · Mean difference (net): 0.080 · 95% CI 0.046 to 0.113
SecondaryChange From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. BL is defined as the mean of the assessments made 30 and 5 minutes (min) pre-dose on Treatment Day 1. Trough FEV1 on Day 85 is defined as the mean of the FEV1values obtained 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 85 is the mean of the FEV1 values obtained 23 and 24 hours after morning dosing on Day 84). Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, day, and day by BL and day by treatment interactions. The model used all available trough FEV1 values recorded on Days 28, 56, 84, and 85. Missing data were not directly imputed in this analysis; however, all non-missing data for a participant were used within the analysis to estimate the treatment effect for trough FEV1 at Day 85.

Time frame:
Baseline and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85
LitersUMEC/VI 62.5/25 µgFSC 500/50 µg
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 850.151 ± 0.01260.062 ± 0.0125

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up contact (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UMEC/VI 62.5/25 µg—7/358 (2%)39/358 (10.9%)
FSC 500/50 µg—2/358 (0.6%)32/358 (8.9%)
Most frequent serious events
Most frequent serious events
EventUMEC/VI 62.5/25 µgFSC 500/50 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/3580/358
Herpes zosterInfections and infestations1/3580/358
SepsisInfections and infestations1/3580/358
Angina pectorisCardiac disorders1/3580/358
Inguinal herniaGastrointestinal disorders0/3581/358
Sudden cardiac deathGeneral disorders1/3580/358
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/3581/358
Renal failure acuteRenal and urinary disorders1/3580/358
Skin burning sensationSkin and subcutaneous tissue disorders1/3580/358
Most frequent other events
Most frequent other events
EventUMEC/VI 62.5/25 µgFSC 500/50 µg
HeadacheNervous system disorders33/35825/358
NasopharyngitisInfections and infestations10/35811/358

Baseline characteristics

Age, Continuous
Age, Continuous(Years)UMEC/VI 62.5/25 µgFSC 500/50 µgTotal
Mean61.8 ± 7.9461.4 ± 8.0661.6 ± 8.00
Sex: Female, Male
Sex: Female, Male(Participants)UMEC/VI 62.5/25 µgFSC 500/50 µgTotal
Female97104201
Male261254515
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UMEC/VI 62.5/25 µgFSC 500/50 µgTotal
White - White/Caucasian/European Heritage358358716
08

Study locations

79 sites
  • GSK Investigational Site
    Benesov, 256 30, Czechia
  • GSK Investigational Site
    Cvikov, 471 54, Czechia
  • GSK Investigational Site
    Kralupy nad Vltavou, 278 01, Czechia
  • GSK Investigational Site
    Kromeriz, 767 55, Czechia
  • GSK Investigational Site
    Praha 5, 150 00, Czechia
  • GSK Investigational Site
    Rokycany, 337 01, Czechia
  • GSK Investigational Site
    Teplice, 415 10, Czechia
  • GSK Investigational Site
    Trebic, 674 01, Czechia
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    København, 2400, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Roskilde, 4000, Denmark
  • GSK Investigational Site
    Dillingen, Bayern 89407, Germany
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Neu isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Delitzsch, Sachsen 04509, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01069, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10629, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Balassagyarmat, 2660, Hungary
  • GSK Investigational Site
    Budaörs, 2040, Hungary
  • GSK Investigational Site
    Debrecen, 4032, Hungary
  • GSK Investigational Site
    Debrecen, 4043, Hungary
  • GSK Investigational Site
    Farkasgyepű, 8552, Hungary
  • GSK Investigational Site
    Gödöllő, 2100, Hungary
  • GSK Investigational Site
    Miskolc, 3529, Hungary
  • GSK Investigational Site
    Mosonmagyaróvár, 9200, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Pecs, H-7621, Hungary
  • GSK Investigational Site
    Szeged, 6722, Hungary
  • GSK Investigational Site
    Szikszó, 3800, Hungary
  • GSK Investigational Site
    Székesfehérvár, 8000, Hungary
  • GSK Investigational Site
    Dordrecht, 3318 AT, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Heerlen, 6419 PC, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Kloosterhaar, 7694 AC, Netherlands
  • GSK Investigational Site
    Sneek, 8601 ZR, Netherlands
  • GSK Investigational Site
    Gdansk, 80-169, Poland
  • GSK Investigational Site
    Inowroclaw, 88-100, Poland
  • GSK Investigational Site
    Krakow, 31-024, Poland
  • GSK Investigational Site
    Poznan, 60-773, Poland
  • GSK Investigational Site
    Skierniewice, 96-100, Poland
  • GSK Investigational Site
    Slupsk, 76-200, Poland
  • GSK Investigational Site
    Barnaul, 656038, Russian Federation
  • GSK Investigational Site
    Blagoveshchensk, 675000, Russian Federation
  • GSK Investigational Site
    Kaluga, 248007, Russian Federation
  • GSK Investigational Site
    Kazan, 420015, Russian Federation
  • GSK Investigational Site
    Khantymansiysk, 628012, Russian Federation
  • GSK Investigational Site
    Moscow, 105 077, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Moscow, 121 309, Russian Federation
  • GSK Investigational Site
    Moscow, 123182, Russian Federation
  • GSK Investigational Site
    Moscow, 123367, Russian Federation
  • GSK Investigational Site
    Nizhniy Novgorod, 603126, Russian Federation
  • GSK Investigational Site
    Orenburg, 460018, Russian Federation
  • GSK Investigational Site
    Petrozavodsk, 185019, Russian Federation
  • GSK Investigational Site
    Ryazan, 390039, Russian Federation
  • GSK Investigational Site
    Saratov, 410028, Russian Federation
  • GSK Investigational Site
    St Pertersburg, 196247, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 194356, Russian Federation
  • GSK Investigational Site
    Tomsk, 634 050, Russian Federation
  • GSK Investigational Site
    Ufa, 450000, Russian Federation
  • GSK Investigational Site
    Barcelona, Catalonia 08017, Spain
  • GSK Investigational Site
    Alicante, 03004, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pama de Mallorca, 07010, Spain
  • GSK Investigational Site
    Ponferrada (León), 24411, Spain
  • GSK Investigational Site
    Valladolid, 47012, Spain
09

References and documents

Publications

  • Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015 Aug 19;15:91. doi: 10.1186/s12890-015-0092-1. PubMed 26286141 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2013
First posted
Apr 2, 2013
Start
Apr 4, 2013
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 7, 2013
Results first posted
May 29, 2014
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01822899
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 2, 2013
Start date
Apr 4, 2013
Primary completion
Oct 1, 2013
Completion
Oct 7, 2013
Results posted
May 29, 2014
Last update
Sep 6, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Umeclidinium bromide · Vilanterol

Start the discussion